FiercePharma2d
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Zacks.com on MSN2d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term Outlook
GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
GSK, Pfizer sales of RSV shots slow as vaccination rates ebb
Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...
GSK Tech Ecosystem Profile - Digital Transformation Strategies and Innovation Programs
The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...
Investors Chronicle2d
GSK bounces back on better outlook and share buybacks
GSK’s lead in vaccines is a cause for concern after mixed political signals in the US, with ardent vaccine sceptic Robert F Kennedy Jr vowing a clampdown on the pharmaceutical industry, which partly ...
Daily6d
GSK Depemokimab applications accepted for review in China, Japan for asthma with type 2 inflammation, CRSwNP
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
GSK announces new drug applications accepted for review in China, Japan
GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...